Italian Biotech for Bioeconomy

Maria Luisa Nolli Assobiotec

Key Enabling Techonologies: un link tra ricerca pubblica e privata

Rome, December 5th 2012

Biotech is a KET

Source: European Commission Communication n. 512 “Preparing for our future: Developing a common strategy for key enabling technologies in the EU”, 2009

Given its prevalence and the significant increase in productivity that it is able to generate, biotechnology is fully included in the so-called Key Enabling Technologies (KET), as also defined by the European Commission. The prerogative of KET is, in fact, to increase the productivity of a system by improving the efficiency of existing processes.

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

The Biotech Industry Meta-sector

Innovation for Sustainable Growth

A growing number of companies operating in «traditional» sectors are integrating biotech products and technology in their production processes in order to improve the quality and the yeald, reducing the environmental impact

No process affect less the environment than natural processes from wich biotechnology derives

Bioeconomy is the challange that Europe is taking up for the estabilishment of a new model of sustainable development that can create value and employment

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Today in Europe bioeconomy is worth more than €2,000 bln and employs more than 22 mln people

Source: Ernst & Young – EuropaBIO 2012

Bioeconomy Impact in Europe

Estimated impact on Italian GDP

The European investment

Stima dell’impatto del biotech sul PIL italiano

…Coming to Horizon 2020, an important aim of the new programme for Research and Innovation for the period 2014-2020, is to address major societal challenges. Building the bio-economy is a prominent part of this approach. Industrial biotechnology and research and innovation activities in the field of bio-based industries have an essential role to play in this regard […] Maire Geoghegan Quinn, Lettera aperta a IFIB 2012

The European investment

EU Support for Innovation

France is the most supportive country for the innovation, whereas Italy still has room for improvement

Direct and indirect government contributions as GDP%

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012 (Italian version)

The Italian Biotech Sector

Companies Employees R&D employees Biotech turnover R&D investments

Total Pure Biotech

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

149 159178

199 211 223 228260

316

369396 394

0

50

100

150

200

250

300

350

400

450

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

394 52,060

6,872 7,075 mln€

1,830 mln€

248 8,330

2,499 1,278 mln€

557 mln€

Analysis by Application Field

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Pure biotech companies Total biotech companies

Small and Micro Companies are the Majority

Size > 80% small and micro < 20% medium 2% big

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Pure biotech companies by size

Geographic Distribution Total Biotech Companies Red Biotech Companies

Colocalization of small&micro pure biotech companies and STP

Biotech companies are mainly concentrated in northern and central Italy Lombardy is the region with the higest number of biotech companies -129

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

The red biotech drives the whole sector

Companies R&D employees Biotech turnover R&D investments

238 5.671

6,811 mln€ 1,691 mln€

141 1.638

1,080 mln€ 491 mln€

Total Pure Biotech

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Product analysis by development phase and type of company

Granted Orphan Drug Designation analysis

The Italian Pipeline

Therapeutic Areas The Italian population is the oldest

in the world: this makes Italy an increasingly interesting scenario for those companies intending to develope and conduct clinical trails on new drugs for the treatment of age-related diseases

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Advanced Therapies

Companies Biotech turnover

33 882 mln€

Geographical distribution

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Green Biotech

By 2015 about half of the global production of food, feed and industrial seeds will be derived from plant varieties developed using one or more biotechnology applications

In the field of agro-biotechnology Italy can count on absolutely unique conditions in its variety of microclimates, biodiversity, and potential market niches

Hence the importance of agro-food diagnostics, for the certification of origin and authenticity of the many Made in Italy products appreciated throughout the world.

Green Biotech

Agro-biotechnology uses modern biotech methods in many applications ranging from improving specific plant varieties, to checking the origin and quality of food and extracting bioactive substances which are available in nature only to a limited extent (molecular pharming).

Companies R&D employees Biotech turnover R&D investments

82 745

103 mln€ 111 mln€

62 431

40 mln€ 41 mln€

Total Pure Biotech

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

White Biotech

Industrial biotechnology uses enzymes and micro-organisms to develop bioproducts in various sectors such as, among others, chemical, paper, textile and bioenergy. The use of renewable raw materials represents in effect one of the most innovative and promising approaches to reduce greenhouse gas emissions

White technologies also allow significant improvement in the output of industrial processes and the value of production in itself, with considerable advantages in terms of economy and environmental protection.

According to OECD estimates, in 2030 industrial and agro-biotechnology will represent overall 75% of the gross added value of the biotech sector

Companies R&D employee Biotech turnover R&D investments

54 456

161 mln€ 28 mln€

40 430

157 mln€ 25 mln€

Total Pure Biotech

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

White Biotech

► Biospecialities: food ingredients, pharmaceuticals, fine chemicals Pharma

► Biospecialities ► Biomaterials: biopolymers, lubrificants, fibers, pigments, protein ► Sugars, Lipids, Proteins, other chemicals: fatty acids, aminoacids, phenols,

antioxidants, fibers, pigments

► Biomaterials ► Base Chemicals: organic acids, I & II metabolites

Cosmesi

Chimico Tessile

► Biofuels: Ethanol, Methane, Hydrogen ► Bioremediation: enzymes, microorganism

Energy – Fuels Bioremediation

Sect

or o

f app

licat

ion

1

2

3

4

The Transversality of the White Biotech

Scientific and Technological Parks

A significant number of pure biotech companies are located within STPs

encouraging the development of true centres of aggregation of researchers, companies and investors

guarantee a network of excellence and consulting services, as well as promotion and support activities for fundraising purpose

acting as intermediaries between the demand for skills and the availability of innovation and financial resources

Source: Ernst & Young – Assobiotec, BioInItaly Report 2012

Industry’s Requirements

High research quality

the poor economic resources for the academic research should be focussed on: the best research teams such ongoing research fields in which Italy could be

effectively competitive on an international level

Valorization of research results

the research projects should fulfill all the requirements to be valorized and transferred to the market - no disclosure before a patent application

a certain Intellectual Property to guarantee a faster negotiation and technology transfer

Networking Market Requirements

Cooperation between different players it is necessary

The bioindustry & pharma associations can act as cluster ‘promoters’

For further info:

www.assobiotec.it

THANKS FOR YOUR ATTENTION